ABBV vs ANET: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Arista Networks, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-06.
AbbVie Inc. · Healthcare
$261.07
+1.2% upside to fair value
Grade C
High Quality
VS
Arista Networks, Inc. · Technology
$169.86
+22.0% upside to fair value
Grade B
High Quality
QuantHub Verdict
ANET has more upside to fair value
(+22.0%).
ANET trades at a lower forward P/E
(56.5x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
ANET |
| Current Price |
$261.07 |
$169.86 |
| Fair Value Estimate |
$264.30 |
$207.23 |
| Upside to Fair Value |
+1.2%
|
+22.0%
|
| Market Cap |
$461.3B |
$213.9B |
| Forward P/E |
128.0x
|
56.5x
|
| EV / EBITDA |
31.0x
|
44.7x
|
| Price / Sales |
7.3x
|
21.7x
|
| Price / FCF |
22.1x
|
39.9x
|
| Revenue Growth YoY |
+12.4%
|
+35.1%
|
| Gross Margin |
70.7%
|
63.5%
|
| Operating Margin |
27.6%
|
42.8%
|
| Return on Equity |
68.0%
|
30.6%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.52%
|
2.51%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology and aesthetics. The company is transitioning from its historical Humira dominance, which has faced loss of exclusivity, toward high-growth assets like Skyrizi and Rinvoq that are driving robust revenue growth of 12.4% in the most recent quarter. Despite strong revenue growth and a dura…
Arista Networks is a leading provider of cloud and AI data-center switching solutions with a durable competitive moat driven by its strong presence among hyperscale cloud customers and AI networking providers. The company benefits from a seasoned management team led by founding CEO Jayshree V. Ullal, who has over 17 years at the helm and deep domain expertise. Arista's financials show robust grow…
Accumulation Zones
| Metric |
ABBV |
ANET |
| Zone Low |
$198.23 |
$155.42 |
| Zone High |
$224.66 |
$176.15 |
| In Buy Zone? |
No
|
Yes
|